FAK inhibitors as promising anticancer targets: present and future directions

Author:

Mustafa Muhamad12ORCID,Abd El-Hafeez Amer Ali34,Abdelhafeez Dalia A5,Abdelhamid Dalia1,Mostafa Yaser A6ORCID,Ghosh Pradipta4789,Hayallah Alaa M2610,A Abuo-Rahma Gamal El-Din12

Affiliation:

1. Department of Medicinal Chemistry, Minia University, Minia, 61519, Egypt

2. Pharmaceutical Chemistry Department, Deraya University, Minia, 61111, Egypt

3. Pharmacology & Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt

4. Department of Cellular & Molecular Medicine, University of California San Diego, La Jolla, CA, USA

5. Department of Pathology, Minia University, Egypt

6. Pharmaceutical Organic Chemistry Department, Assiut University, 71526, Egypt

7. Department of Medicine, University of California San Diego, La Jolla, CA, USA

8. Rebecca & John Moore Comprehensive Cancer Center, University of California San Diego, La Jolla, CA, USA

9. Veterans Affairs Medical Center, La Jolla, CA, USA

10. Pharmaceutical Chemistry Department, Sphinx University, New Assiut, Egypt

Abstract

FAK, a nonreceptor tyrosine kinase, has been recognized as a novel target class for the development of targeted anticancer agents. Overexpression of FAK is a common occurrence in several solid tumors, in which the kinase has been implicated in promoting metastases. Consequently, designing and developing potent FAK inhibitors is becoming an attractive goal, and FAK inhibitors are being recognized as a promising tool in our armamentarium for treating diverse cancers. This review comprehensively summarizes the different classes of synthetically derived compounds that have been reported as potent FAK inhibitors in the last three decades. Finally, the future of FAK-targeting smart drugs that are designed to slow down the emergence of drug resistance is discussed.

Publisher

Future Science Ltd

Subject

Drug Discovery,Pharmacology,Molecular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3